once-daily immunosuppressive regimen in kidney transplant recipients

Study to evaluate the safety and efficacy of sirolimus combined with low-dose extended-release tacrolimus in kidney transplant recipients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063697

Enrollment

Unknown

Registered

2022-09-14

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplantation

Interventions

study group:Tac-ER+SRL

control group:Tac+MPA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Kidney transplant recipients; 2) The age of the recipient is > 18 years old and = 65 years old; 3) Preoperative population reactive antibody = 10%.

Exclusion criteria

Exclusion criteria: 1) There are signs of systemic or local active important infection; 2) ABO-incompatible kidney transplant recipients; 3) Kidney transplant recipients who have undergone combined multi-organ transplantation.

Design outcomes

Primary

Measure	Time frame
kidney function;	—

Secondary

Measure	Time frame
incidence of rejection;Graft and Recipient Survival;adverse event rate;medication adherence;	—

Countries

China

Contacts

Public ContactZhang weijie

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology

wjzhangtj@126.com13387522365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026